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Abstract
Background: The CHD7 (Chromodomain Helicase DNA binding protein 7) gene encodes a member of the
chromodomain family of ATP-dependent chromatin remodeling enzymes. Mutations in the CHD7 gene are found
in individuals with CHARGE, a syndrome characterized by multiple birth malformations in several tissues. CHD7 was
identified as a binding partner of PBAF complex (Polybromo and BRG Associated Factor containing complex)
playing a central role in the transcriptional reprogramming process associated to the formation of multipotent
migratory neural crest, a transient cell population associated with the genesis of various tissues. CHD7 is a large
gene containing 38 annotated exons and spanning 200 kb of genomic sequence. Although genes containing such
number of exons are expected to have several alternative transcripts, there are very few evidences of alternative
transcripts associated to CHD7 to date indicating that alternative splicing associated to this gene is poorly
characterized.
Findings: Here, we report the cloning and characterization by experimental and computational studies of a novel
alternative transcript of the human CHD7 (named CHD7 CRA_e), which lacks most of its coding exons. We
confirmed by overexpression of CHD7 CRA_e alternative transcript that it is translated into a protein isoform
lacking most of the domains displayed by the canonical isoform. Expression of the CHD7 CRA_e transcript was
detected in normal liver, in addition to the DU145 human prostate carcinoma cell line from which it was originally
isolated.
Conclusions: Our findings indicate that the splicing event associated to the CHD7 CRA_e alternative transcript is
functional. The characterization of the CHD7 CRA_e novel isoform presented here not only sets the basis for more
detailed functional studies of this isoform, but, also, contributes to the alternative splicing annotation of the CHD7
gene and the design of future functional studies aimed at the elucidation of the molecular functions of its gene
products.
Background
The CHD7 (Chromodomain Helicase DNA binding pro-
tein 7) gene encodes a member of the chromodomain
family of ATP-dependent chromatin remodeling
enzymes. In 2004, CHD7 was described as the major
gene involved in the CHARGE syndrome [1], a complex
genetic disorder related to multiple birth malformations
and functional disorders, including ocular coloboma (C),
heart disease (H), choanal atresia (A), retarded growth
and/or anomalies of the central nervous system (R), gen-
ito-urinary defects and/or hypogonadism (G), and ear
anomalies and/or deafness (E) [2]. De novo mutations in
the CHD7 gene, especially nonsense and frameshift
mutations, are found in approximately 60% of the indivi-
duals with CHARGE [1-4]. Embryonic lethality at E10.5-
E11.5 in mice which are homozygous for null mutations
in Chd7 support the haplo-insufficiency model as the
most likely mechanism involved in this syndrome. Addi-
tionally, mice which are heterozygous for null mutations
in Chd7 recapitulate many of the traits found in indivi-
duals with CHARGE, including defects in the eye, heart,
choanae, genitals and inner ear [5].
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in transcription control through ATP-dependent chro-
matin remodeling [6,7]. Firstly, members of the chromo-
domain family share a unique combination of functional
domains. In CHD7, these domains are the two N-term-
inal chromodomains thought to mediate binding to
methylated histones [6], two SWI2/SNF2-like ATPase/
helicase domains, a DNA and/or modified histones
binding domain [6], and two BRK (BRM and KIS)
domains of unknown function [8]. Secondly, it was
recently demonstrated that CHD7 associates with PBAF,
a chromatin-remodeling subcomplex of the SWI/SNF
(Swich 2/Sucrose Non-fermentable 2) family, and it is
essential for the activation of the transcriptional pro-
gram associated with the formation of multipotent
migratory neural crest, a transient cell population with a
multilineage differential pot e n t i a l[ 7 ] .T h i sc e l lp o p u l a -
tion is associated with the genesis of various body struc-
tures including the peripheral nervous system, pigment
cells, craniofacial skeleton and cardiac structures
[7,9,10]. Therefore, it is assumed that the mechanistic
link between the CHARGE syndrome pathogenesis and
the CHD7 protein would be its potential role in regulat-
ing embryonic development by affecting chromatin
structure and gene expression.
Some important questions remain open regarding
CHD7 function. One of these questions is related to
alternative splicing associated to the CHD7 locus. CHD7
is a relatively large gene containing 38 annotated exons
and spanning approximately 200 kilobases of genomic
sequence. Although it is expected that large genes con-
taining several exons, like CHD7, would produce various
alternative transcripts [11], to date, very few examples
are available of alternative transcripts associated to this
gene, suggesting that alternative splicing associated to
the CHD7 gene is underestimated and far from being
annotated. Although alternative splicing events related
to CHD genes remains largely unexplored, Duplin, a
CHD8 isoform generated by alternative splicing with a
crucial role in embryogenesis, is an example of the com-
plexity of gene products that can be potentially pro-
duced from CHD loci [12]. In this context,
characterization of alternatively spliced transcripts
related to the CHD7 locus is fundamental for the design
of future functional studies.
In the present study, we have characterized the exon-
intron structure of a novel CHD7 alternative transcript
and its expression profile at mRNA level in some
human cell lines and normal human tissues. This alter-
native transcript misses most of CHD7 coding exons,
being translated as a CHD7 isoform lacking most of the
domains presented in the canonical isoform. We named
this novel transcript and its encoded protein isoform
CHD7 CRA_e, following the existing CHD7 isoform
nomenclature and will keep to this nomenclature in this
study.
Methods
Cell lines
The following human cell lines: DU145 prostate
carcinoma, HepG2 hepatocarcinoma, transformed 293 T
kidney embryonic, Skmel-25 malignant melanoma, NCI-
H1155 lung carcinoma, IM-9 B transformed lymphoblast,
SAOS 2 osteosarcoma and HeLa cervix adenocarcinoma
were cultured as previously described [13] and recom-
mended by [14].
Reverse transcription and polymerase chain reaction
In order to obtain the coding sequence of the canonical
isoform of the CHD7 gene, total RNA samples from
diverse tumor cell lines were purified according to the
Chirgwin procedure [15]. Poly A
+ RNA was isolated from
total RNA with the PolyAttract mRNA isolation kit (Pro-
mega, Madison, WI) and employed for cDNA synthesis.
cDNA was synthesized using 1 μgo fp o l yA
+ RNA,
oligodT12-18 and the Superscript III reverse transcriptase
(Invitrogen, Carlsbad, CA), according to manufacturer’s
instruction. PCR reactions were carried out in 25 μl and
the reactions mixtures contained 1 μl of a 1/20 dilution
of the cDNA preparation, 1× Tuning Buffer® (Eppendorf,
Westbury, NY), dNTPs (0.5 mM each), 0.5 μM of each
primer and 0.5 U TripleMaster Taq polymerase (Eppen-
dorf, Westbury, NY). The following primers annealing
to sequences corresponding to exons 1 and 38 of CHD7
were used:
CHD7F forward: 5’-AAAAAGCAGGCTTGGTCC-
TCGCCACGCGCTCGTGCTCGGGA-3’ and CHD7R
reverse: 5’-AGAAAGCTGGGTGGGACATCTCTGCA-
TATCATGGGTCACT-3’.
A “Long distance PCR” cycling protocol was
employed, as follows: 3 min at 93°C (initial denatura-
tion); 14 cycles of 20 sec at 93°C and 10 min at 68°C; 21
cycles of 20 sec at 93°C and 11 min at 68°C with addi-
tional 20 sec of auto-extension at each cycle; 7 min at
68°C (final extension).
To analyze the expression of the CHD7 novel splicing
variant by RT-PCR, its sequence was used to design a
set of primers flanking the splicing site at exons 3
(CHD7 E3 forward 5’-AGTGCTGGGATACCAATGGA-
3’) and 36 (CHD7 E36 reverse 5’-GGAACCCCCATA-
CAGTCAAA-3’), which would yield a PCR band of
approximately 2 kbp. Expression of the long transcript
from the NOTCH2 gene was evaluated as an internal
control using the following primers corresponding to
the 5’ region of the transcript:
NOTCH2 forward 5’-ACTGTGGCCAACCAGTT-
CTC-3’ and NOTCH2 reverse 5’-CTCTCACAGG-
TGCTCCCTTC-3’, which would yield a PCR band of
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synthesized using Superscript III reverse transcriptase
(Invitrogen, Carlsbad, CA), according to manufacturer’s
instruction and 1.5 μg of total RNA from the DU145
prostate carcinoma cell line and from various human
tissues (spinal cord, prostate, kidney, lung, placenta, ske-
letal muscle and liver) obtained from the Human Total
RNA Master Panel II (Clontech, Mountain View, CA).
Polymerase chain reactions (final volumes 50 μl) con-
taining 1× Phusion HF Buffer (Finnzymes, Finland), 0.5
mM each dNTP, 0.4 uM each primer, 1 ul of the undi-
luted cDNAs preparations, and 2 U Phusion Hot Start
DNA Polymerase (Finnzymes, Finland) were carried out
to detect the novel CHD7 alternative isoform and
NOTCH2 transcripts in the cDNA samples mentioned
above. The cycling protocol employed for the detection
of CHD7 CRA_e transcript was as follows: 30 sec at
98°C (initial denaturation); 3 cycles of 10 sec at 98°C, 30
s e ca t6 8 ° Ca n d1 2m i na t7 2 ° C ;3c y c l e so f1 0s e ca t
98°C, 30 sec at 65°C and 12 min at 72°C; 3 cycles of 10
sec at 98°C, 30 sec at 62°C and 12 min at 72°C; 35
cycles of 10 sec at 98°C, 30 sec at 60°C and 12 min at
72°C; and a 15 min at 72°C (final extension). The
cycling protocol employed for the detection of NOTCH2
transcript was as follows: 4 min at 94°C (initial dena-
turation); 35 cycles of 30 sec at 94°C, 45 sec at 54°C and
45 sec at 72°C; and a 10 min at 72°C (final extension).
A negative control, without cDNA, was run with each
reaction. PCR products were fractionated by agarose gel
electrophoresis and visualized under UV light and the
digital images were acquired using the D-Transillumina-
tor and MiniBIS gel documentation system (DNR Bio-
Imaging Systems, Israel).
Sequence analysis of the novel CHD7 transcript
In order to characterize the novel CHD7 transcript, its
coding sequence was re-amplified from a cDNA pre-
paration synthesized using the Superscript III reverse
transcriptase (Invitrogen, Carlsbad, CA), according to
manufacturer’s instructions, and 3 μg of total RNA from
DU145 prostate carcinoma cell line. PCR reactions were
carried out in 50 μl and the reactions mixtures con-
tained 1 μl of a 1/20 dilution of the cDNA preparation,
1× High Fidelity Buffer® (Eppendorf, Westbury, NY),
dNTPs (0.4 mM each), 0.4 μMo fe a c hp r i m e ra n d4U
TripleMaster Taq polymerase (Eppendorf, Westbury,
NY). The following primers annealing to sequences cor-
responding to exons 2 and 38 of CHD7 were used:
CHD7F forward: 5’-ACCTCAGTGAAGTGAAGCA-
CAGG-3’ and CHD7R reverse: 5’-CACACTAGCGTG-
GAGATTGTCAG-3’. The cycling protocol employed
was as follows: 3 min at 94°C (initial denaturation); 1
cycle of 30 sec at 94°C and 12 min at 72°C; 3 cycles of
30 sec at 94°C, 40 sec at 68°C and 12 min at 72°C; 3
cycles of 30 sec at 94°C, 40 sec at 65°C and 12 min at
72°C; 35 cycles of 30 sec at 94°C, 40 sec at 62°C and 12
min at 72°C; and a 15 min at 72°C (final extension).
The approximately 3.3 kpb DNA band was gel purified
and subcloned into the pGEM-T Easy vector (Promega,
Madison, WI) using the TA cloning system, according
to manufacturer’s instruction. Three bacterial (Escheri-
chia coli XL1 Blue) clones (pGEM-M1, pGEM-M2 and
pGEM-M3) were picked and individually grown in
liquid LB medium containing 100 μg/ml of ampicilin
overnight at 37°C under agitation (250 rpm). Plasmid
DNA was extracted from bacterial cultures using the
GFX TM Micro Plasmid Prep (GE HealthCare, Piscat-
away, NJ), according to the manufacturer’s instructions.
The three clones containing the novel CHD7 transcript
cDNA were subjected to sequencing using the ABI 3700
sequencer and the BigDye 3.1 sequencing kit (Applied
Biosystems, Foster City, CA) at the GaTE (Genomic and
Transposable Elements) lab, Biological Institute, Univer-
sity of Sao Paulo. Sequencing was carried out using
sequencing primers annealing to CHD7 exons 2, 37 and
38. The novel CHD7 transcript cDNA sequences (clones
M1, M2 and M3) were individually clustered into con-
tigs using the SeqMan II software (DNASTAR, Inc.,
Madison, WI). The original sequencing files were evalu-
ated for quality using the Trace Quality Evaluation algo-
rithm within SeqMan II. Poor-quality sequences were
trimmed and the trimmed cDNA sequences of each
clone were assembled into contigs using the SeqMan II
assembly process. The contig cDNA sequences of each
clone were individually compared to the canonical
CHD7 transcript reference sequence (NM_017780.2)
using the BLASTN program [16] at NCBI [17]. Determi-
nation of sequence overlap between the contig cDNA
sequences described above and the CHD7 canonical
transcript reference sequence and CHD7 mRNAs and
spliced ESTs sequences from the Genbank was per-
formed using the UCSC Genome Browser [18,19]. The
contig cDNA sequences were aligned to the February
2009 version of the human genome sequence assembly
using the BLAT alignment tool provided by UCSC. The
contigs cDNA sequences open reading frames (ORFs)
were determined using the ORFinder tool at [20].
Translations of the detected ORFs were submitted
to alignment to CHD7 reference protein sequence
(Genbank:
NP_060250.2) using the BLASTP alignment
tool [21].
Cloning of the CHD7 CRA_e isoform coding sequence
into a bicistronic lentiviral expression vector
The CHD7 CRA_e isoform coding sequence from clones
M1, M2 and M3 were amplified by PCR from pGEMT-
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into the p156RRLsinPPTCMVIRESPRE third generation
transfer bicistronic lentiviral vector [22] (heretofore
referred to as pLV-EGFP). This pLV-EGFP bicistronic
vector was kindly provided by Prof. Inder Verma (The
Salk Institute, San Diego, California) and further modi-
fied in our lab by Dr. Juan Carlos Bustos Valenzuela to
add the 5’-XbaI-EcoRV-MluI-NheI-PstI-XhoI-BamHI-3’
multiple cloning site. Polymerase chain reactions (final
volumes 50 μl) containing 1× HiFi Buffer (Eppendorf,
Westbury, NY), 0.2 mM each dNTP, 0.25 uM each pri-
mer, 50 ng of the template plasmids, and 2 U Triple
Master DNA Polymerase (Eppendorf, Westbury, NY)
were carried out to obtain the CHD7 novel isoform cod-
ing sequences from clones M1, M2 and M3. The follow-
ing primers were used: VL XhoI IM CHD7 forward: 5’-
CCCCTCGAGATGGCAGATCCAGGAATG-3’ and VL
BamHI IM CHD7 reverse: 5’-CCCGGATCCCTT-
GAACTGGAACTGGTACTGG-3’. The cycling para-
meters were as follows: 2 min at 94°C (initial
denaturation); 24 cycles of 30 sec at 94°C, 30 sec at 58°
C and 4 min at 68°C; and 10 min at 68°C (final exten-
sion). The purified PCR products were digested by XhoI
a n dB a m H Ia n ds u b - c l o n e di n t ot h ep L V - E G F Pv e c t o r
digested with the same enzymes.
Lentivirus particles production and transduction of
DU145 cells
Lentivirus particles containing the M1, M2 and M3
cDNA clones of the CHD7 CRA_e isoform and control
EGFP lentiviral expression vectors were produced by
transient transfection into 293 T cells. Briefly, 2 × 10
6
cells were plated in 6-cm diameter Petri dishes 16 h
prior to transfection in Dulbecco’s modified Eagle med-
ium (DMEM) supplemented with 10% fetal bovine
serum (Hyclone, Logan, UT), ampicilin (25 μg/ml),
streptomycin (100 μg/ml) and 1.2 g/l of sodium bicarbo-
nate in a humidified atmosphere of 2% CO2 in air at 37°
C. A sample (total of 5 μg) of plasmid DNA was
employed for transfection, as follows: 2.2 μgo ft h e
transfer vector plasmid, 1.45 μg of packaging plasmid
pMDL (Invitrogen, Carlsbad, CA), 570 ng of the pREV
expression vector (Invitrogen, Carlsbad, CA) and 790 ng
of the pVSVG envelope plasmid (Invitrogen, Carlsbad,
CA). These plasmids were co-transfected into 293 T
cells by lipofection using the Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. After 5 h of transfection,
the medium was replaced and the conditioned medium
containing the pseudo-lentiviral particles were harvested
24, 48 and 72 h after transfection, cleared by low-speed
centrifugation and stored at -80°C. For titration of the
lentiviral preparations, serial dilutions of the conditioned
medium were used to transduce 10
5 293 T cells as
described elsewhere [23]. The transduction efficiency
was estimated by counting EGFP-positive cells under a
fluorescence microscope (TE300 Nikon, Japan). The
viral titer of each preparation was calculated according
to the following formula:
Titer cfu/ml P N/1 V 1 DF () =× ×× () / , 00
where P = % EGFP+ cells, N = number of cells at the
time of transduction (10
5), V = volume of dilution used
for transduction and DF = dilution factor.
For transduction of DU145 cells, 2 × 10
4 cells in sus-
pension were mixed with samples of lentivirus superna-
tants at a MOI (Multiplicity of Infection) of 10 in the
presence of polybrene (10 μg/ml). After mixing, the
DU145 cells were plated in 48-well dishes and cultured
i nt h ep r e s e n c eo fl e n t i v i r u sf o r1 6h o u r s .C e l l sw e r e
analyzed for EGFP expression 72 hours after
transduction.
Protein extraction
DU145 cells and the transduced DU145 cells generated
as described in the item above (DU145 M1, DU145 M2,
DU145 M3 and DU145 EGFP) were plated (1.5 × 10
6
cells) in 6-cm diameter Petri dishes and grown over-
night. The culture medium was then removed and the
cell monolayers were rinsed twice and then scrapped
with cold PBSA. The cell suspensions were transferred
to microcentrifuge tubes and pelleted for 5 min at 200
× g at 4°C. The cells were resuspended in RIPA
+ buffer
(10 mM Tris-HCl pH 7.5, 1% sodium deoxycholate, 1%
NP-40, 150 mM NaCl, 0.1% SDS, 1 mM DTT and 1×
protease inhibitors cocktail (GE HealthCare, Piscataway,
NJ) and incubated on ice for 15 min. Cell lysates were
then homogenized by passing through an insulin syringe
several times. Finally, cellular debris was removed by
centrifugation (20,000 × g for 30 min) at 4°C and the
extracts were stored at -70°C. The protein concentration
in these extracts was determined using the Bradford
assay.
Western blot analysis
Protein samples (30-40 μg) obtained from cell lysates
were fractionated in 6% SDS-polyacrylamide gel electro-
phoresis. The resolved proteins were electro-blotted
onto nitrocellulose membranes (Bio-Rad, Hercules, CA),
which were blocked with 5% non-fat milk in TBS buffer
containing 0.05% Tween 20, overnight at 4°C. After six
washes with TBS/0.05% Tween 20, the membranes were
incubated with antibodies against CHD7 (1:400 dilution)
(ab31824 - Abcam, Cambridge, UK) in the same buffer
containing 5% non-fat milk for 1 h at room tempera-
ture. The membranes were washed again and then
probed with horseradish peroxidase-conjugated
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CA), in the same buffer, for 40 min at room tempera-
ture. PACE (Paired basic amino acid cleaving enzyme)
detection using the polyclonal antibody against PACE
(sc-20801 - Santa Cruz Biotechnology, Santa Cruz, CA)
was used (1:500 dilution) as an internal control. The sig-
nals were detected using the ECL-Plus detection system
(GE HealthCare, Piscataway, NJ) according to the manu-
facturer’s instructions.
Results
Identification of a novel CHD7 alternative transcript by
RT-PCR from the human prostate carcinoma cell line
DU145
In order to clone the full-length CHD7 transcript, we
designed primers on exons 1 and 38 of CHD7,w h i c h
would yield an RT-PCR product of approximately 10.3
kbp (Figure 1a). RT-PCR reactions using these primers
and poly A
+ RNA samples from eight human cell lines
yielded a DNA band of approximately 10 kbp in most of
the samples (Figure 1b). Additionally, a band of approxi-
mately 9 kbp was also detected in RNA samples from
three cell lines (HepG2, DU145 and HeLa) and another
one of approximately 3.3 kbp in the human prostate
carcinoma cell line DU145 (Figure 1b).
Re-amplification, cloning and sequencing of the 3.3 kbp
DNA band followed by BLAST alignment of its sequence
against the human transcripts database revealed that it
constituted an alternative transcript of the CHD7 gene.
Structural analysis of this sequence revealed an alternative
exon-intron boundary in this alternative transcript, which
was formed by an alternative exonic donor site at exon 3
1 2000 4000 6000 8000 10000
CHD7 ORF AAAA
1 38 2
CHD7 
478 9471
(A)
10  –
L
a
d
d
e
r
C
(
-
)
H
e
p
G
2
2
9
3
T
D
U
1
4
5
S
K
m
e
I
H
1
1
5
5
I
M
-
9
S
a
o
s
H
e
L
a
~ 10kbp
(kbp)
(B)
3 –
5 –
~ 3.3kbp
Figure 1 Identification of a putative novel splice variant of CHD7. (A) Representation of the full-length CHD7 transcript structure and
primers used to amplify it. At the top the nucleotide sequence numbering scheme of the full-length transcript is represented. At the middle is a
schematic representation of the full-length CHD7 transcript with its ORF indicated as a box (the ORF initial and final nucleotides numbers are
indicated below the box). At the bottom the exon-intron structure of CHD7 is represented. Exons are represented as black rectangles and
intronic sequences as a thin line. The sites of the ORF initial and final nucleotides (dotted lines) and the primers (arrows) annealing to sequences
corresponding to exons 1 and 38 of the CHD7 transcript sequence (deposited under the accession number NM_017780.2) used for the
amplification of the full-length CHD7 transcript are indicated. (B) Amplification of the full-length CHD7 transcript by RT-PCR. Poly A
+ RNA was
extracted from the indicated cell lines, and reverse transcription followed by PCR was performed using the CHD7 primers set depicted in (A).
Aside from the predicted 10 kbp band, additional RT-PCR products of approximately 9 kbp (not indicated) and 3.3 kbp (indicated) were
detected. C(-) is the negative control (PCR reaction without cDNA).
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2a). The sequence of this alternative transcript (CHD7
CRA_e) was deposited at Genbank [Genbank: GU060498].
Sequence analysis of the sequences flanking the alternative
splicing sites present in the CHD7 CRA_e transcript
revealed the presence of highly conserved sequences asso-
ciated with splicing (Table 1). In addition, alignment of
the sequences flanking the alternative splicing sites in the
CHD7 CRA_e alternative transcript with the correspon-
dent exonic regions of the CHD7 orthologs found in Gen-
bank revealed a high level of sequence conservation
around the putative splicing elements (Figure 2b). In some
instances (Sus scrofa, Bos taurus and Gallus gallus), a
markedly increased sequence conservation around the
alternative splice sites was observed (Figure 2b).
The CHD7 alternative transcript consensus sequence
was aligned to the February 2009 version of the human
genome sequence assembly provided by the University
of California, Santa Cruz (UCSC), using the BLAT
search tool to compare the CHD7 CRA_e alternative
transcript exon-intron structure with CHD7 known
mRNA sequences and known spliced ESTs. No human
CHD7 transcripts or spliced ESTs aligning to the CHD7
locus presented an exon-intron structure similar to that
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kbp
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Overall nucleotides
identity
99%
94%
92%
89%
88%
---
SD BP SA
Local nucleotides
identity
100%
97%
94%
89%
94%
---
5---C A G G T T A G T--------C A G A T G T G C T G T T T T C C C C A T T T C A  A A ---3 Monodelphis dom.  (XM_001368235.1)
5’---C A G G T C A G C--------C A G A C G T G C T C T T T T C C C C G T T T C A G A---3’ Rattus norvegicus  (NM_001107906.1)
5’---C A G G T T A G T--------C A G A T G T G C T G T T T T C C T C A T T T C A G A ---3’ Sus scrofa (XR_045625.1)
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Figure 2 Analysis of the exon-intron structure of the CHD7 CRA_e novel transcript.( A )I nt h eu p p e rp a r to ft h ef i g u r et h ee x o n - i n t r o n
structure of the canonical CHD7 gene (accession number NM_017780.2) is represented. Exons 4 to 35 have been omitted for clarity. In the lower
part the exon-intron structure of the CHD7 CRA_e alternative transcript deduced from sequencing and annealing to the canonical transcript
sequence is represented. Splicing is represented as bold lines and numbers below boxes indicate the exon numbers. Rectangles represent the
exons, with 0.25 cm in length being equivalent to 100 nucleotides, and the bold line represents the introns, with 0.5 cm being equivalent to 10
kilobase pairs. Regions of alternatively spliced exons 3 and 36 are lightly shaded. (B) Comparative alignment of nucleotide sequences around
exonics splicing sites at exons 3 and 36 of human CHD7 with the corresponding exonics regions in Chimpanzee, Horse, Dog, Mouse, short-tailed
Opossum, Rat, Boar, Cattle and Chicken. The splicing donor (SD), putative branch point (BP) and splicing acceptor (SA) sites are boxed. The
pyrimidine-rich region is shown in bold. Nucleotides differing from the human sequence are underlined.
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(data not shown).
Analysis of the putative protein generated by the novel
CHD7 alternative transcript
The ORFinder tool predicts that the novel CHD7
CRA_e transcript encodes a putative protein of 948
amino acids with a predicted molecular mass of
approximately 100 kDa. Alignment of the putative pro-
tein encoded by the novel CHD7 transcript [GenBank:
ACY35999.1] against the canonical CHD7 protein
sequence [GenBank: NP_060250] showed that the for-
mer lacks most of the central portion and conserves
only the N and C-termini of the canonical protein
(Figure 3a). Furthermore, a Conserved Domain Data-
base search at NCBI indicated that the putative protein
retains only one conserved domain present in
the canonical CHD7 protein, namely the BRK domain
[GenBank: smart00592] located at its C-terminus
(Figure 3b).
To confirm, by Western blot analysis, whether the
novel CHD7 CRA_e transcript is in fact translated into
a1 0 0k D ap r o t e i n ,w es u b - c l o n e di t sc o d i n gs e q u e n c e
into the bicistronic lentiviral pLV-EGFP expression vec-
tor and overexpressed CHD7 CRA_e isoform in the
DU145 prostate carcinoma cell line. This cell line was
separately transduced with vector constructions contain-
ing the coding sequences of each of all three different
clones (CHD7 pLV-M1, CHD7 pLV-M2 and CHD7
pLV-M3) of the novel transcript and, also, with the vec-
tor containing only the EGFP coding sequence, as a
negative control. Sequencing of these three CHD7
CRA_e cDNA clones (M1, M2 and M3) revealed that
M2 and M3 displayed nonsense mutations in their
sequences, causing a premature stop-codon and putative
truncated proteins at amino acids 718 and 285, respec-
tively. The M1 clone sequencing revealed four missense
mutations (M80T, V323A, T408A and K797E). Since
the antibody used in this Western blot analysis recog-
nizes the C-terminus end of the CHD7 protein (residues
2,950-2,997 in the canonical protein or residues 901-948
in the novel isoform), the cells transduced with the
C H D 7p L V - M 2a n dC H D 7p L V - M 3e x p r e s s i o n sc o n -
structs were also used as negative controls in addition
to the non-transduced DU145 cells.
This Western blot analysis revealed that the novel
CHD7 transcript is translated into a protein that is spe-
cifically recognized by the CHD7 antibody, displaying an
apparent molecular mass of 145 kDa (Figure 3c). Immu-
noprobing of the ubiquitously expressed PACE was
employed as the loading control.
Expression analysis of the CHD7 CRA_e alternative
transcript through RT-PCR in normal human tissues
In order to evaluate whether the novel CHD7 CRA_e
transcript is also expressed in normal human tissues
besides the DU145 prostate tumoral cell line, we
designed an RT-PCR assay to specifically detect its
expression, by employing primers which specifically
anneal to sequences flanking the alternative splice site
of this transcript, generating a DNA fragment of
approximately 2 kbp. We used samples of total RNA
from normal human tissues (kidney, liver, lung, placenta,
prostate, skeletal muscle and spinal cord) from a com-
mercially available total RNA pannel, as described in
Methods. DU145 cells total RNA was used as a positive
control for the reaction. A negative control, without
cDNA, was run with each reaction. In addition to
DU145 cells, expression of the novel CHD7 CRA_e
transcript was detected only in the liver RNA sample
(Figure 4). This result was confirmed using two other
primer sets flanking the splice region (data not shown).
Analysis of NOTCH2 expression was used as an internal
control.
Discussion
Here, we describe a novel alternative transcript of the
CHD7 gene, which lacks most of its 38 exons, of which
37 are coding. This novel CHD7 transcript is likely to
be expressed at low abundance and/or in a restricted set
of tissues, since no corresponding mRNA or EST has
been deposited in public sequence databases to date.
Our findings suggest that CHD7 CRA_e is a functionally
significant alternative transcript and not an aberrant
Table 1 Analysis of the sequences flanking the alternative splice sites of the CHD7 CRA_e alternative transcript
Alternative
transcript
Donor splice
site location
(nt)
a
Acceptor
splice site
location
(nt)
a
Intron size
/kb
EXON/intron/EXON
(consensus splice sequence)
b
5’ CAG|guragu...cu/gac/u(y)10 15nyag|G) 3’
CHD7
CRA_e
Exon 3 (47) Exon 36 (112) 81 5’ CAG|guuagu...cagaugugcuguuuuccuauuucag|A 3’
a) Location of the exonics donor and acceptor splice sites of the CHD7 CRA_e alternative transcript. The numbers in parenthesis represent the exonic splicing
sites at exons 3 and 36; b) The consensus sequence associated to splice donor, branch and acceptor sites according to Padgett [30] and Keller and Noon [31].
The vertical lines represent either 5’ or 3’ splice site and the putative branch point is underlined. The sequence of the investigated splice site in the CHD7 CRA_e
transcript is represented below the consensus splice sequence. Nucleotides identity between the consensus and the investigated splice sites are shown in bold
r = purine (A or G); y = pyrimidine (C or U)
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Page 7 of 11CHD7 CRA_e      MADPGMMSLFGEDGNIFSEGLEGLGECGYPENPVNPMGQQMPIDQGFASLQPSLHHPSTN 60
CHD7 CRA_a      MADPGMMSLFGEDGNIFSEGLEGLGECGYPENPVNPMGQQMPIDQGFASLQPSLHHPSTN 60
************************************************************
CHD7 CRA_e      QNQTKLTHFDHYNQYEQQKMHLMDQPNRMMSNTPGNGLASPHSQYHTPPVPQVPHGGSGG 120
CHD7 CRA_a      QNQTKLTHFDHYNQYEQQKMHLMDQPNRMMSNTPGNGLASPHSQYHTPPVPQVPHGGSGG 120
************************************************************
CHD7 CRA_e      GQMGVYPGMQNERHGQSFVDSSSMWGPRAVQVPDQIRAPYQQQQPQPQPPQPAPSGPPAQ 180
CHD7 CRA_a      GQMGVYPGMQNERHGQSFVDSSSMWGPRAVQVPDQIRAPYQQQQPQPQPPQPAPSGPPAQ 180
************************************************************
CHD7 CRA_e      GHPQHMQQMGSYMARGDFSMQQHGQPQQRMSQFSQGQEGLNQGNPFIATSGPGHLSHVPQ 240
CHD7 CRA_a      GHPQHMQQMGSYMARGDFSMQQHGQPQQRMSQFSQGQEGLNQGNPFIATSGPGHLSHVPQ 240
************************************************************
CHD7 CRA_e      QSPSMAPSLRHSVQQFHHHPSTALHGESVAHSPRFSPNPPQQGAVRPQTLNFSSRSQTVP 300
CHD7 CRA_a      QSPSMAPSLRHSVQQFHHHPSTALHGESVAHSPRFSPNPPQQGAVRPQTLNFSSRSQTVP 300
************************************************************
CHD7 CRA_e      SPTINNSGQYSRYPYSNLNQGLVNNTGMNQNLGLTNNTPMNQSVPRYPNAVGFPSNSGQG 360
CHD7 CRA_a      SPTINNSGQYSRYPYSNLNQGLVNNTGMNQNLGLTNNTPMNQSVPRYPNAVGFPSNSGQG 360
************************************************************
CHD7 CRA_e      LMHQQPIHPSGSLNQMNTQTMHPSQPQGTYASPPPMSPMKAMSNPAGTPPPQVRPGSAGI 420
CHD7 CRA_a      LMHQQPIHPSGSLNQMNTQTMHPSQPQGTYASPPPMSPMKAMSNPAGTPPPQVRPGSAGI 420
************************************************************
CHD7 CRA_e      PMEVGSYPNMPHPQPSHQPPGAMGIGQRNMGPRNMQQSRPFIGMSSAPRELTGHMRPNGC 480
CHD7 CRA_a      PMEVGSYPNMPHPQPSHQPPGAMGIGQRNMGPRNMQQSRPFIGMSSAPRELTGHMRPNGC 480
************************************************************
CHD7 CRA_e      PGVGLGDPQAIQERLIPGQQHPGQQPSFQQLPTCPPLQPHPGLHHQSSPPHPHHQPWAQL 540
CHD7 CRA_a      PGVGLGDPQAIQERLIPGQQHPGQQPSFQQLPTCPPLQPHPGLHHQSSPPHPHHQPWAQL 540
************************************************************
CHD7 CRA_e      HPSPQNTPQKVPVHQHSPSEPFLEKPVPDMTQ---------------------------- 572
CHD7 CRA_a      HPSPQNTPQKVPVHQHSPSEPFLEKPVPDMTQVSGPNAQLVKSDDYLPSIEQQPQQKKKK 600
********************************                            
CHD7 CRA_e      -----------------------------------------KPKQKRHRCRNPNKLDINT 591
CHD7 CRA_a      VGEDAPKNKDLVEWLKLHPTYTVDMPSYVPKNADVLFSSFQKPKQKRHRCRNPNKLDINT 2640
*******************
CHD7 CRA_e      LTGEERVPVVNKRNGKKMGGAMAPPMKDLPRWLEENPEFAVAPDWTDIVKQSGFVPESMF 651
CHD7 CRA_a      LTGEERVPVVNKRNGKKMGGAMAPPMKDLPRWLEENPEFAVAPDWTDIVKQSGFVPESMF 2700
************************************************************
CHD7 CRA_e      DRLLTGPVVRGEGASRRGRRPKSEIARAAAAAAAVASTSGINPLLVNSLFAGMDLTSLQN 711
CHD7 CRA_a      DRLLTGPVVRGEGASRRGRRPKSEIARAAAAAAAVASTSGINPLLVNSLFAGMDLTSLQN 2760
(A)
_ Q
************************************************************
CHD7 CRA_e      LQNLQSLQLAGLMGFPPGLATAATAGGDAKNPAAVLPLMLPGMAGLPNVFGLGGLLNNPL 771
CHD7 CRA_a      LQNLQSLQLAGLMGFPPGLATAATAGGDAKNPAAVLPLMLPGMAGLPNVFGLGGLLNNPL 2820
************************************************************
CHD7 CRA_e      SAATGNTTTASSQGEPEDSTSKGEEKGNENEDENKDSEKSTDAVSAADSANGSVGAATAP 831
CHD7 CRA_a      SAATGNTTTASSQGEPEDSTSKGEEKGNENEDENKDSEKSTDAVSAADSANGSVGAATAP 2880
************************************************************
CHD7 CRA_e      AGLPSNPLAFNPFLLSTMAPGLFYPSMFLPPGLGGLTLPGFPALAGLQNAVGSSEEKAAD 891
CHD7 CRA_a      AGLPSNPLAFNPFLLSTMAPGLFYPSMFLPPGLGGLTLPGFPALAGLQNAVGSSEEKAAD 2940
************************************************************
CHD7 CRA_e      KAEGGPFKDGETLEGSDAEESLDKTAESSLLEDEIAQGEELDSLDGGDEIENNENDE 948
CHD7 CRA_a      KAEGGPFKDGETLEGSDAEESLDKTAESSLLEDEIAQGEELDSLDGGDEIENNENDE 2997
*********************************************************
1 2997
1 948
BRK domain SWI2/SNF2domain
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Figure 3 Deduced protein sequence coded by the CHD7 CRA_e alternative transcript and respective Western blot analysis.( A )
Alignment of the putative amino acids sequence coded by the CHD7 CRA_e alternative transcript with the amino acids sequence of the
canonical CHD7 protein (accession number: NP_060250). The amino acids in bold and subtitled are conserved in the BRK domain (smart00592).
The amino acids from the canonical CHD7 protein that are missing in the CHD7 CRA_e putative amino acid sequence were omitted for clarity
(amino acids 601 to 2580). The numbers on the right refer to the amino acids at the end of each line related to each sequence. (B) Schematic
representation of the domain structure of canonical CHD7 protein and CHD7 CRA_e isoform. (C) Western blot analysis of DU145 cells stably
expressing CHD7 CRA_e alternative transcript (DU145 M1) using an anti-CHD7 antibody which recognizes the C-terminus end of CHD7. Parental
DU145 cells and cells transduced with the empty vector (DU145 EGFP) or stably expressing two additional clones of CHD7 CRA_e alternative
transcript, which putatively code for truncated proteins (DU145 M2 and DU145 M3) were used as negative controls. Detection of the PACE
protein expression is shown as an internal protein loading control.
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Page 8 of 11transcript or splice event associated with a specific cell
line or cancer cells. Firstly, we could detect highly con-
served sequences associated with splicing events flanking
the splice sites of CHD7 CRA_e at exons 3 and 36. Also,
a human EST [GenBank: BI039198.1] is available, sup-
porting the fact that the exonic donor site is functional
(data not shown). Additionally, splice consensus
sequences flanking the splice site of CHD7 CRA_e are
highly conserved in various species (Figure 2b). The
observed high level of conservation in the sequences of
some species proximal to the alternative splice site as
well as within the alternatively spliced region related to
CHD7 CRA_e splice event indicates that cis-elements
may be associated with splicing control in this region.
However, considering that the alternative splicing sites
are part of the coding region, the conservation observed
could also be due to a highly conserved domain in this
region. Secondly, detection of the CHD7 CRA_e tran-
script in normal human liver total RNA, in addition to
the DU145 prostate carcinoma cell line, is an indication
that this alternative CHD7 transcript is also expressed in
normal human tissues.
Our molecular analysis predicted that the CHD7
CRA_e alternative transcript encodes a 101 kDa protein.
A commercially available antibody raised against the C-
terminal end of mouse CHD7 allowed us to detect a dis-
tinct protein band with an apparent molecular mass of
145 kDa in the total protein extract of DU145 cells
overexpressing the CHD7 CRA_e isoform. Currently, we
cannot offer an evidence-based explanation for this dis-
crepancy between the theoretical and the experimentally
obtained values for the molecular mass of the CHD7
CRA_e isoform. One possibility is that CHD7 is subject
to phosphorylation and/or a myriad of post-translational
modifications, similarly to several other helicases and
nuclear proteins. If that is the case, CHD7 CRA_e may
undergo phosphorylation or other modifications, which
could partially explain its different mobility in SDS-
PAGE gels. It is interesting to note that the CHD7
CRA_e translated sequence harbors six Serine/Gluta-
mine (SQ) and two Threonine/Glutamine (TQ) motifs,
which are known to be putative phosphorylation sites
for the DNA damage response kinases, namely: ATM
(Ataxia-Telangiectasia Mutated) and ATR (Ataxia-Tel-
angiectasia and Rad3-related) [24]. In fact, proteomic
analysis demonstrated that ATM phosphorylates at least
one of these motifs [25]. If one can show that these ser-
ine/threonine residues are phosphorylated in CHD7
CRA_e, this could partially explain the mobility discre-
pancy, as well as would implicate CHD7 CRA_e as a
putative ATM/ATR substrat e ,w i t hap o s s i b l er o l ei n
DNA damage response and repair. However, additional
possibilities other than post-translational modifications
that could account for the CHD7 CRA_e isoform unex-
pected SDS-PAGE mobility could be a) a particular
amino acid composition that could lead to an anoma-
lous migration on SDS-PAGE as it is described for some
proteins, for example, the CTCF (CCCTC binding fac-
tor) transcription factor [26] and b) an artifact related to
the artificial overexpression of CHD7 CRA_e, maybe an
aggregate resistant to reduction by 2-mercaptoethanol
and/or solubilization by SDS. Additionally, we could not
detect endogenous CHD7 CRA_e at the protein level by
Western blot, either in total or nuclear-enriched protein
extracts obtained from the DU145 cells despite the
detection of a protein band of approximately 350 kDa,
which most likely corresponds to the full-length CHD7
isoform, and, also, additional protein bands which could
represent additional isoforms or degradation products
(data not shown). This suggests that the CHD7 CRA_e
isoform may be expressed at very low levels at least in
DU145 cells.
Analysis of the CHD7 CRA_e predicted protein
revealed that only the extreme N-terminal and C-
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Figure 4 RT-PCR analysis of the CHD7 CRA_e transcript expression in normal human tissue total RNA samples. To detect the novel
CHD7 transcript by RT-PCR we used primers adjacent to the alternative splice site which generate a DNA fragment of approximately 2 kbp. As
internal control of the reaction we performed RT-PCR of the same samples using primers specific for the NOTCH2 transcript which yield a DNA
fragment of approximately 300 bp (lower part of the figure). A negative control without cDNA was run with each reaction.
Colin et al. BMC Research Notes 2010, 3:252
http://www.biomedcentral.com/1756-0500/3/252
Page 9 of 11terminal regions of the canonical protein are maintained
in this novel isoform (Figure 3b). Thus, CHD7 CRA_e
isoform lacks most of the characteristic domains of the
CHD7 protein, retaining only one BRK domain in its C-
terminal region. The function of the BRK domain is
unknown, but it was first described in Drosophila CHD7
ortholog KIS protein and is also found in BRM
(Brahma) which is another chromatin-remodeling pro-
tein [8]. It is hypothesized that the BRK domain may
interact with chromatin components, which are unique
to higher eukaryotes, since it is not present in yeast
chromatin-remodeling factors, such as SWI2/SNF2 and
STH1 (SNF Two Homolog 1) [8]. Considering that the
chromodomains and ATPase/helicase domains are likely
to be critical for the function of the CHD7 protein, the
discovery of a CHD7 isoform lacking these domains is
quite interesting and intriguing. If this isoform retains
the ability to interact with DNA and/or proteins related
to chromatin remodeling, it could act as a regulatory
protein in this process rather than acting as a helicase,
like the full-length protein.
A question that emerges with the description of this
novel CHD7 isoform, and probably of other isoforms in
the near future, is whether individuals with CHARGE
carrying mutations affecting both the full-length and the
shorter isoforms differ with respect to clinical features
from individuals with mutations affecting only the full-
length and not the shorter isoforms. Apparently, patho-
genic mutations (stop-codon, frameshift, missense and
exon-intron boundary mutations) are scattered through-
out the CHD7 coding exons in approximately 60% of
individuals with CHARGE. Some of the described muta-
tions are on exons 2, 3, 36, 37 and 38 and would also
affect the CHD7 CRA_e isoform, but most of the
described mutations occur in other exons and would
affect only the full-length isoform [1-4]. However, a gen-
otype-phenotype correlation study of CHD7 mutation-
positive CHARGE individuals revealed no clear correla-
tion between the type of mutation and clinical findings
[4]. In fact, different clinical phenotypes were observed
either between non-related individuals carrying the
same mutation or even between twins, suggesting that
additional factors could be involved in CHARGE patho-
genesis such as variable chromatin methylation profiles
among these individuals caused by differential epigenetic
regulation [4].
Finally, the CHD7 gene has recently been shown to be
involved with the pathogenesis of other diseases, in
addition to the CHARGE syndrome. Before the full-
length structure of this gene was resolved, it had been
described that the protein encoded by KIAA1416, a par-
tial CHD7 transcript, is a colon tumor antigen, which is
overexpressed in colon cancer cells [27]. Moreover, rear-
rangements at CHD7 locus have recently been associated
to small-cell lung cancer [28]. Furthermore, CHD7 has
been found to be mutated in idiopathic hypogonadotro-
pic hypogonadism and Kallmann syndrome [29]. Alto-
gether, further knowledge on the CHD7 isoforms
(including CHD7 CRA_e) and their biological roles
should significantly impact our current understanding of
several diseases, including developmental disorders and
cancer.
Conclusions
Here we described the exon/intron structure of a novel
splicing variant of the human CHD7 gene, detected its
expression at the mRNA level in at least one human
normal tissue (liver) and confirmed that this novel tran-
script is translated into a protein of apparent molecular
mass of 145 kDa. We believe that characterization of
the CHD7 CRA_e novel isoform presented here not
only sets the basis for more detailed functional studies
of this isoform, but, also, contributes to the alternative
splicing annotation of the CHD7 gene.
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